Advertisement
Q&A: 'Imagine if healthcare were priced to consumers'

Q&A: 'Imagine if healthcare were priced to consumers'

By Modern Healthcare  |  February 14, 2015

Mark Ganz, president and CEO of Cambia Health Solutions, a not-for-profit parent of 22 companies offering healthcare products and services, discusses how his companies are seeking to make healthcare more consumer-directed.

Hep C drug price war likely to slow Gilead’s growth

By Jaimy Lee  |  February 06, 2015

The soaring sales and profits reported by Gilead Sciences in 2014 aren't likely to be repeated as the company begins to offer steeper discounts on its blockbuster hepatitis C treatments Sovaldi and Harvoni.

Gilead's 2014 profit margin nears 50%, fueled by hep C drugs

By Jaimy Lee  |  February 03, 2015

Gilead Sciences, the Foster City, Calif.-based drugmaker, said sales of its blockbuster hepatitis C duo topped $3.8 billion in the fourth quarter of 2014, fueling quarterly revenue that doubled to $7.3 billion and $3.5 billion in profits.

Gilead promotes two to executive VP

By Adam Rubenfire  |  February 03, 2015

Gilead Sciences, the biopharmaceutical company, announced the promotion of two employees to executive vice president positions. Dr. Andrew Cheng has been promoted to executive VP of HIV therapeutics and development operations, and Taiyin Yang has been promoted to executive VP of pharmaceutical...

Insurers eye pharma discounts beyond hepatitis C

By Bob Herman  |  February 02, 2015

The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs.

Tamiflu controversy reignited by new study

By Sabriya Rice  |  January 29, 2015

The antiviral medication Tamiflu shortened the length of time patients experienced flu symptoms, and reduced rates of complications and hospitalizations from the virus, a new study finds. But it did not have an effect on those with flu-like symptoms who did not have the flu.

Harvard Pilgrim secures discount on Gilead's newest hep C drug

By Bob Herman  |  January 29, 2015

Harvard Pilgrim Health Care, one of the largest not-for-profit health insurers in New England, said it will save millions of dollars in hepatitis C drug costs through its negotiated pricing discount from pharmaceutical giant Gilead Sciences.

Obamacare legal challenge downplayed by business leaders

Obamacare legal challenge downplayed by business leaders

By Bob Herman  |  January 17, 2015

The nation's largest healthcare organizations predicted a profitable 2015 at the annual J.P. Morgan Healthcare Conference in San Francisco. They forecast that the biggest cloud on the horizon—the pending U.S. Supreme Court case challenging the Obamacare premium subsidies—would pass...

Aetna inks discount deal for Gilead's hepatitis C drugs

Aetna inks discount deal for Gilead's hepatitis C drugs

By Bob Herman  |  January 16, 2015

Aetna has agreed to a deal with Gilead Sciences to give preference to the drugmaker's hepatitis C drugs. It's the fourth straight agreement where a payer or benefits manager has chosen Gilead over competitor AbbVie.

Are hep C exclusivity deals taking power from doctors?

Are hep C exclusivity deals taking power from doctors?

By Virgil Dickson  |  January 12, 2015

Exclusivity deals for hepatitis C drugs by pharmacy benefit managers and a major health plan have raised concerns that the decision of which drug is best for a patient is being taken away from clinicians.

Advertisement
Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It's the only news you need each day.